Page 1

GenSight BIOLOGICS Press Release . GenSight Biologics Reports Interim Financial Results for the First Half of 2021 and Provides Operational Update • Operating loss significantly reduced by lower R & D expenses and revenues generated from LUMEVOQⓇ ATUs in France Ramp up of Sales & Marketing in preparation of the expected commercial launch of LUMEVOQⓇ in Europe in H1 2022 • Successful refinancing in Q1 2021 secures mid - 2023 runway • Multiple regulatory and clinical milestones expected in Q4 2021 - Paris , France , July 29 , 2021 , 7.30 am CEST GenSight Biologics ( Euronext : SIGHT , ISIN : FR0013183985 , PEA - PME eligible ) , a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders , today reported its interim financial results for the first half of 2021 and provided recent operational updates . The full interim financial report is available on the Company's website in the Investors section . The 2021 half - year financial statements were subject to a limited review by the Company's statutory auditors and approved by the Board of Directors on July 28 , 2021 . " LUMEVOQ has demonstrated robust and consistent data in three independent Phase III trials , showing impressive evidence of clinical benefit and a strong safety profile . Based on this data package , we are now moving forward with the regulatory , manufacturing , and commercial steps necessary for obtaining marketing authorization in Europe and North America , " commented Bernard Gilly , co - founder and Chief Executive Officer of GenSight Biologics . “ We are building our organization to ensure a smooth and speedy commercial launch in Europe , and we look forward to bringing LUMEVOQ to more patients with Leber Hereditary Optic Neuropathy and helping to change their lives for the better . " 2021 Half - Year Financial Results In million euros Revenues H1 2020 H1 2021 0.7 5.6 Other income 2.6 1.3 Operating income 3.3 6.9 Research and development expenses ( 12.0 ) ( 8.0 ) Sales and marketing expenses ( 0.9 ) ( 2.3 ) General and administrative expenses ( 4.0 ) ( 3.3 ) Operating profit ( loss ) ( 13.6 ) ( 6.7 ) Net income ( loss ) * ( 14.7 ) ( 8.3 ) EPS ( in € per share ) * ( 0.45 ) ( 0.19 ) Net cash flows from operating activities ( 6.7 ) ( 10.2 ) Net cash flows from investment activities ( 0.1 ) 0.2 Net cash flows from financing activities 4.4 26.4